Diagnostics Instrument Maker AutoGenomics Files Again for IPO
Published: Oct 02, 2012
AutoGenomics, a Vista, CA-based company that specializes in molecular diagnostics systems, has filed for a $65 million Initial Public Offering (IPO), according to a recent regulatory filing. The company, founded in 1999, plans to trade on Nasdaq under the ticker symbol AGMX. The filing marks the second IPO attempt for the diagnostic instrument company. AutoGenomics previously filed for an $86.3 million IPO in mid-2008, but withdrew the offering in 2011. AutoGenomics makes an automated molecular diagnostic instrument that can be used to identify specific genetic signatures in personalized medicine, women’s health, oncology, and infectious disease. The company says it offers 50 tests for use with its flagship “Infinity” gene analyzer, with 15 more under development. So far, the FDA has cleared the company’s Infinity analyzer and five genetic tests.